37 88

Cited 0 times in

Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study

 Yae Jee Baek  ;  Youn-Jung Lee  ;  So Ra Park  ;  Kyoo Hyun Kim  ;  Seung-Hoon Beom  ;  Choong-Kun Lee  ;  Sang Joon Shin  ;  Sun Young Rha  ;  Sinyoung Kim  ;  Kyoung Hwa Lee  ;  Jung Ho Kim  ;  Su Jin Jeong  ;  Nam Su Ku  ;  Jun Yong Choi  ;  Joon-Sup Yeom  ;  Minkyu Jung  ;  Jin Young Ahn 
 CANCER RESEARCH AND TREATMENT, Vol.55(3) : 746-757, 2023-07 
Journal Title
Issue Date
Antibodies ; COVID-19 Vaccines / adverse effects ; COVID-19* / prevention & control ; Humans ; Neoplasms* / therapy ; Prospective Studies ; SARS-CoV-2 ; Vaccines*
COVID-19 vaccine ; Chemotherapy ; Immunogenicity ; Reactogenicity ; Solid cancer
Purpose We aimed to assess the humoral response to and reactogenicity of coronavirus disease 2019 (COVID-19) vaccination according to the vaccine type and to analyze factors associated with immunogenicity in actively treated solid cancer patients (CPs).

Materials and Methods Prospective cohorts of CPs, undergoing anticancer treatment, and healthcare workers (HCWs) were established. The participants had no history of previous COVID-19 and received either mRNA-based or adenovirus vector–based (AdV) vaccines as the primary series. Blood samples were collected before the first vaccination and after 2 weeks for each dose vaccination. Spike-specific binding antibodies (bAbs) in all participants and neutralizing antibodies (nAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wild-type, Delta, and Omicron variants in CPs were analyzed and presented as the geometric mean titer.

Results Age-matched 20 HCWs and 118 CPs were included in the analysis. The bAb seroconversion rate and antibody concentrations after the first vaccination were significantly lower in CPs than in HCWs. After the third vaccination, antibody levels in CPs with a primary series of AdV were comparable to those in HCWs, but nAb titers against the Omicron variant did not quantitatively increase in CPs with AdV vaccine as the primary series. The incidence and severity of adverse reactions post-vaccination were similar between CPs and HCWs.

Conclusion CPs displayed delayed humoral immune response after SARS-CoV-2 vaccination. The booster dose elicited comparable bAb concentrations between CPs and HCWs, regardless of the primary vaccine type. Neutralization against the Omicron variant was not robustly elicited following the booster dose in some CPs, implying the need for additional interventions to protect them from COVID-19.
Files in This Item:
T202304689.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers
Yonsei Authors
Ku, Nam Su(구남수) ORCID logo https://orcid.org/0000-0002-9717-4327
Kim, Kyoo Hyun(김규현)
Kim, Sin Young(김신영) ORCID logo https://orcid.org/0000-0002-2609-8945
Kim, Jung Ho(김정호) ORCID logo https://orcid.org/0000-0002-5033-3482
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Baek, Yae Jee(백예지)
Beom, Seung Hoon(범승훈) ORCID logo https://orcid.org/0000-0001-7036-3753
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Ahn, Jin Young(안진영) ORCID logo https://orcid.org/0000-0002-3740-2826
Yeom, Joon Sup(염준섭) ORCID logo https://orcid.org/0000-0001-8940-7170
Lee, Kyoung Hwa(이경화) ORCID logo https://orcid.org/0000-0003-0033-1398
Lee, Choong-kun(이충근) ORCID logo https://orcid.org/0000-0001-5151-5096
Jung, Min Kyu(정민규) ORCID logo https://orcid.org/0000-0001-8281-3387
Jeong, Su Jin(정수진) ORCID logo https://orcid.org/0000-0003-4025-4542
Choi, Jun Yong(최준용) ORCID logo https://orcid.org/0000-0002-2775-3315
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.